SGMT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
15.8M
+35.0%
11.7M
+8.8%
10.8M
-24.9%
14.3M
+20.2%
11.9M
R&D
11.5M
+64.9%
7.0M
+3.9%
6.7M
-30.8%
9.7M
+34.2%
7.2M
SG&A
4.3M
-9.2%
4.7M
+17.0%
4.0M
-12.4%
4.6M
-1.6%
4.7M
Operating Income
-15818000
-35.0%
-11713000
-8.8%
-10765000
+24.9%
-14334000
-20.2%
-11925000
EBITDA
-15818000
-35.0%
-11713000
-8.8%
-10765000
+24.9%
-14334000
-20.2%
-11925000
Net Income
-13953000
-31.0%
-10650000
-11.3%
-9568000
+25.9%
-12908000
-24.3%
-10386000
EPS (Basic)
$-0.26
+21.2%
$-0.33
-13.8%
$-0.29
+27.5%
$-0.40
-25.0%
$-0.32
EPS (Diluted)
$-0.26
+21.2%
$-0.33
-13.8%
$-0.29
+27.5%
$-0.40
-25.0%
$-0.32
Shares (Diluted)
53.1M
+63.1%
32.6M
+0.1%
32.5M
+0.2%
32.5M
+0.8%
32.2M
Sagimet Biosciences (SGMT) โ€” Financials